We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

126 hedge funds and large institutions have $249M invested in CytomX Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.45% more ownership

Funds ownership: 79.76% → 82.21% (+2.4%)

2% more capital invested

Capital invested by funds: $243M → $249M (+$5.62M)

3% less funds holding

Funds holding: 130 → 126 (-4)

16% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 51

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
126
Holders Change
-4
Holders Change %
-3.08%
% of All Funds
2.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
43
Reduced
51
Closed
15
Calls
$88K
Puts
–
Net Calls
+$88K
Net Calls Change
+$22K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$14.4M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$2.46M
3
Morgan Stanley
Morgan Stanley
New York
+$2.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.58M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$2.3M
2
BlackRock
BlackRock
New York
-$2.15M
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$1.85M
4
Norges Bank
Norges Bank
Norway
-$1.76M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
GIM
26
Granahan Investment Management
Massachusetts
$1.83M -$360K -50,338 -15%
ACM
27
Altium Capital Management
New York
$1.79M +$1.96M +273,703 New
Man Group
28
Man Group
United Kingdom
$1.75M +$323K +45,174 +20%
Massachusetts Financial Services
29
Massachusetts Financial Services
Massachusetts
$1.68M -$18.4K -2,570 -1%
Axa
30
Axa
France
$1.57M +$561K +78,524 +49%
Russell Investments Group
31
Russell Investments Group
United Kingdom
$1.5M -$1.85M -259,428 -53%
Goldman Sachs
32
Goldman Sachs
New York
$1.49M -$374K -52,374 -19%
Assenagon Asset Management
33
Assenagon Asset Management
Luxembourg
$1.43M +$328K +45,887 +27%
Citadel Advisors
34
Citadel Advisors
Florida
$1.21M -$683K -95,660 -34%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.16M -$37.2K -5,207 -3%
Point72 Asset Management
36
Point72 Asset Management
Connecticut
$819K +$893K +125,000 New
AQR Capital Management
37
AQR Capital Management
Connecticut
$812K +$13.8K +1,937 +2%
Grantham, Mayo, Van Otterloo & Co (GMO)
38
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$754K -$789K -110,416 -49%
CS
39
Credit Suisse
Switzerland
$709K -$217K -30,411 -22%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$656K -$13.6K -1,900 -2%
Wells Fargo
41
Wells Fargo
California
$654K -$53.6K -7,496 -7%
PPA
42
Parametric Portfolio Associates
Washington
$646K -$868K -121,471 -55%
PAM
43
Panagora Asset Management
Massachusetts
$645K -$1.24M -173,252 -64%
Los Angeles Capital Management
44
Los Angeles Capital Management
California
$632K -$26.3K -3,685 -4%
Swiss National Bank
45
Swiss National Bank
Switzerland
$616K +$19.3K +2,700 +3%
Thrivent Financial for Lutherans
46
Thrivent Financial for Lutherans
Minnesota
$593K – – –
Barclays
47
Barclays
United Kingdom
$589K +$432K +60,474 +205%
SO
48
STRS Ohio
Ohio
$582K +$83.6K +11,700 +15%
Deutsche Bank
49
Deutsche Bank
Germany
$572K -$211K -29,565 -25%
PAG
50
Private Advisor Group
New Jersey
$571K -$171K -24,003 -22%
1
2
3 4 5

CTMX Hedge Fund Activity: Q4 2020 in Review

126 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2020, worth a combined $249M — up 2.3% from $243M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CTMX and 11 opened new positions — a net loss of 4 holders — while 51 trimmed existing stakes and 43 added.

The largest buyer was BVF Inc, adding an estimated $14.4M. The largest seller was First Manhattan, exiting entirely with an estimated $2.3M sold.

  • 126 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2020, down from 130 in Q3 2020.
  • Funds reported $249M of CytomX Therapeutics stock for Q4 2020, up 2.3% quarter-over-quarter.
  • 11 funds opened new CytomX Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
  • The largest CytomX Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14.4M added.
  • The largest CytomX Therapeutics seller in Q4 2020 was First Manhattan, an estimated $2.3M sold.

Based on aggregated 13F filings for Q4 2020.